Should low-risk DCIS lose the cancer label? An evidence review.
Saved in:
| Title: | Should low-risk DCIS lose the cancer label? An evidence review. |
|---|---|
| Authors: | Ma T; School of Public Health, The University of Sydney, Sydney, NSW, 2006, Australia., Semsarian CR; School of Public Health, The University of Sydney, Sydney, NSW, 2006, Australia., Barratt A; School of Public Health, The University of Sydney, Sydney, NSW, 2006, Australia.; Wiser Healthcare, Sydney, Australia., Parker L; Sydney School of Pharmacy, Charles Perkins Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.; Department of Radiation Oncology, Royal North Shore Hospital, Sydney, Australia., Pathmanathan N; Western Sydney Local Health District, Sydney, Australia.; Westmead Breast Cancer Institute, Westmead Hospital, Sydney, Australia., Nickel B; School of Public Health, The University of Sydney, Sydney, NSW, 2006, Australia., Bell KJL; School of Public Health, The University of Sydney, Sydney, NSW, 2006, Australia. katy.bell@sydney.edu.au. |
| Source: | Breast cancer research and treatment [Breast Cancer Res Treat] 2023 Jun; Vol. 199 (3), pp. 415-433. Date of Electronic Publication: 2023 Apr 19. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
